后来发现小鼠中存在与wingless基因同源的基因int1,该基因的激活可导致小鼠乳腺增生和肿瘤发生,因此明确了Wnt通路与癌症的关系9。 目前已鉴别的Wnt信号通路有三条:经典Wnt信号通路、非经典Wnt/平面细胞极化通路(noncanonical Wnt/planar cell ...
[5]. Zhenfang Du and Christine M. Lovly. Mechanisms of receptor tyrosine kinase activation in cancer. Molecular Cancer, 2018. doi:10.1186/s12943-018-0782-4 [6]. Bahar ME, Kim HJ, Kim DR. Targeting the RAS/RA...
Prostate cancer lineage plasticity is a key driver in the transition to neuroendocrine prostate cancer (NEPC), and the RTK/RAS signaling pathway is a well-established cancer pathway. Nevertheless, the comprehensive link between the RTK/RAS signaling path
Mutations of the FLT3, c-KIT, c-FMS, KRAS, NRAS, BRAF and CEBPA genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal-transduction pathway are frequent in acute myeloid leukemia (AML). We examined 140 patients with therapy-related myelodysplasia or AML (t-MDS/t-AML) for point mut...
RTK-RAS pathway mutation is enriched in myeloid sarcomaNGS based Cancer panel design, Variant detection algorithm design & implementation, Interpretation of cancer genome profiledoi:10.1038/s41408-018-0083-6Choi, MihongJeon, Yoon KyungSun, Choong-Hyun...
In lung cancer, inhibition of MEK in the RAS pathway has been shown to activate upstream receptor tyrosine kinases (RTK). Genomic studies of MPNST samples have shown that 30% of tumors have amplification of the RTKs MET and EGFR. Furthermore, in a study of the genomic progression of a ...
PDGFRβ-upregulated tumour cells have low activated RAS levels and, when treated with PLX4032, do not reactivate the MAPK pathway significantly. In another subset, high levels of activated N-RAS resulting from muta-tions lead to significant MAPK pathway reactivation upon PLX4032 treatment. ...
Tan, PBO, Kim, SK (1999) Signaling specificity: the RTK/RAS/MAP kinase pathway in metazoans. Trends Genet 15: pp. 145-149Tan PB, Kim SK: Signaling specificity: The RTK/RAS/MAP kinase pathway in metazoans. Trends Genet 1999, 15: 145–149....
(D) GSEA showing the significantly enriched KRAS signaling pathway comparing KMT2D-low versus KMT2D-high LUSC tumors (TCGA LUSC dataset). (E) Western blot showing ERK, phospho-ERK (pERK), and b-actin in Kmt2dKO (...
A minority of LUAD cases (20-25%) lack apparent genetic alterations in this pathway, and thus are ineligible for most targeted therapies. These candidate "oncogene negative" LUADs may harbor novel classes of oncogenic drivers or represent a biologically distinct class of tumors. To characterize ...